Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial
Deonna M Ackermann, Amelia K Smit, Monika Janda, Cathelijne H van Kemenade, Mbathio Dieng, Rachael L Morton, Robin M Turner, Anne E Cust, Les Irwig, Jolyn K Hersch, Pascale Guitera, H Peter Soyer, Victoria Mar, Robyn PM Saw, Donald Low, Cynthia Low, Dorothy Drabarek, David Espinoza, Jon Emery, Peter Murchie Show all
Trials | BMC | Published : 2021
BACKGROUND: Most subsequent new primary or recurrent melanomas might be self-detected if patients are trained to systematically self-examine their skin and have access to timely medical review (patient-led surveillance). Routinely scheduled clinic visits (clinician-led surveillance) is resource-intensive and has not been shown to improve health outcomes; fewer visits may be possible if patient-led surveillance is shown to be safe and effective. The MEL-SELF trial is a randomised controlled trial comparing patient-led surveillance with clinician-led surveillance in people who have been previously treated for localised melanoma. METHODS: Stage 0/I/II melanoma patients (n = 600) from dermatolog..View full abstract
Awarded by National Health and Medical Research Council (NHMRC)
This research project is funded by a National Health and Medical Research Council (NHMRC) Project grant (#1163054). The funder had no role in the design of the study and will have no role in the collection, analysis, and interpretation of the data; the writing of the report; or the decision to submit the report for publication.